Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

INTRODUCTION: Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to <...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacokinet
Egile Nagusiak: Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2021
Gaiak:
Original Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8195962/
https://ncbi.nlm.nih.gov/pubmed/33565026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00966-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak